Background

Start strategy. The company starts its activity with manufacturing low-tonnage sophisticated active pharmaceutical ingredients (API) such as nitroglycerin and isosorbide dinitrate for solid and liquid dosage forms.

Production process improvement forces to switch over to the continuous nitroglycerin synthesis process with increased safety and pharmacopoeia purity level of received APIs. Introduction of the unique process unit solves the problem of contamination by heavy metals, which is typical for nitroglycerin of Russian origin that was widely used in that period for manufacturing finished dosage forms.

Watershed in the company’s history. First registered finished dosage forms are marketed in Ukraine: sublingual sprays Nitro-Mik™ and Iso-Mik™. These drugs created on the basis of nitroglycerin and isosorbide dinitrate allow treating one of the most severe manifestation of ischemic heart disease – angor pectoris. Preparations initiate the cardiological portfolio, which is supplemented by no less acute and sophisticated dosage forms in the following years. The principle “We make the very best affordable” in the concept of new products development has been taken as the basis of the company’s corporate strategy.

Further expansion of the company’s portfolio due to introduction of a new therapeutic direction. Start of manufacturing drugs for treating neurological disturbances of various genesis. Armadin (ethylmethylhydroxypyridine succinate) and Trizipin (trimethylhydrazinium propionate dihydrate) have been marketed. This step strengthens considerably the company’s positions in the rating of domestic manufacturers and, more importantly, enables increasing significantly investments to new developments.

Efforts of the company’s research center allow manufacturing the next development, which is unique in Ukraine – solid dosage form with modified release of its active ingredient based on micropellets. The technology, which allows ensuring the complex profile of API release with any set characteristics and high accuracy, has been applied in manufacture of Dicor Long with modified release of isosorbide dinitrate. Clinical trials of Dicor Long using the bioequivalence procedure with the highest level of evidence proved the equivalence of the company’s developments to the original German drug. Success in the prolongation technologies enables creating original drugs. In particular, the company obtained the permit for marketing tableted Armadin long and Trizipin long with modified release of isosorbide dinitrate. This innovation enhances the commitment of therapy patients and decreases the cost of neurological and cardiological disturbance treatment without any losses of efficiency. The company’s business geography expands gradually. In accordance with the results of 2012, Pharmaceutical company Microkhim was awarded twice in the National Business Rating of Ukraine in the field of foreign economic activity “Exporter of the Year” – “Importer of the Year”. In 2013, the company was awarded “Gold Symbol of National Goods and Services Quality” by the decision of the Scientific and Expert Council for the program “Leaders of XXI Century” as the appreciation of the company’s efforts in the field of quality management.

To enhance access to European quality drugs for Ukrainian patients, we initiated cooperation with INIBSA, Spanish pharmaceutical company in the field of injectable Armadin and Trizipin.

Anniversary year for the company. The 25-years intensive and creative work of its business team resulted in the unique developments in the field of APIs and finished dosage forms, product portfolio of 34 brands in four therapeutic groups, considerable pool of new and urgent products, which are at different stages of marketing permit issue. The trust to the company’s products increases: Armadin was the winner in the nomination “Best Prescription Medicine in Neurology” at the seventeenth national contest of professionals in pharmaceutical industry “Panacea”.